In the United States, the options currently available for cardiac ablation use thermal mechanisms to ablate tissue and cause cell death. Radiofrequency ablation (RFA) treatment uses energy to heat the tissue until it dies, resulting in its inability to transmit electrical signals that trigger arrhythmias. Cryoballoon ablation (CBA) uses a super-cooled balloon at the end of a catheter to freeze the tissue for the same result. Thermal methods for ablation have been successfully used for years; however, these methods carry uncommon yet serious risks.

The Latest Developments in Cardiac Ablation

November 2, 2023 — The latest STRIKE-PE data, presented by Penumbra, Inc. at the Vascular Interventional Advances Conference, VIVA23, showed that computer assisted vacuum thrombectomy (CAVT) for the treatment of pulmonary embolism is safe and effective at reducing right heart strain, and also improved clinical and functional outcomes.

November 2, 2023 — The University of Maryland Medical Center (UMMC) released a statement on the passing of a patient with terminal heart disease who received the world’s second genetically-modified pig heart transplant. DAIC is sharing the October 31 statement in its entirety below.

November 2, 2023 — Contego Medical Inc. announced the presentation of late-breaking clinical results from the PERFORMANCE II carotid stent trial at the annual Vascular InterVentional Advances, VIVA 23, being held by the Viva Foundation Oct. 30-Nov.

November 2, 2023 — The second round of late-breaking clinical trials results from the Vascular InterVentional Advances Conference, VIVA23, have been announced, with results from three trial outcomes presented in the Oct. 31 afternoon session.

October 31, 2023 — Results of four late-breaking clinical trials presented during the The VEINS Conference 2023, taking place Oct. 28-30 in Las Vegas, NV have been announced in a summary news release by The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research.

October 31, 2023 — Edwards Lifesciences Corporation announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two contemporary mitral transcatheter edge-to-edge repair (

October 31, 2023 — SMT (Sahajanand Medical Technologies), a leading medical device company in India, focused on innovative patient care in cardiovascular segment, today announced positive results of its recent clinical trial 

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now